top of page
CDH2026
Our Research
STARLIGHT Initiative
Project PRESCIENT
Tumor Models Catalog

Welcome!

The Cancer Discovery Hub (CDH) is a one-stop pan-omics diagnostic and research core laboratory housed at the National Cancer Centre Singapore. We specialise in state-of-the-art research-grade technologies and provide expert support to investigators on all cancer related projects.

Home: Welcome

Latest news

Key events and achievements

  • 11 Sep 2026 : Collaboration with Agilent Technologies

  • 06 Feb 2026 : Collaboration research agreement with Lucence and Dxd Hub 

  • 10 Nov 2025 : Collaborative research agreement with 10X Genomics

  • 08 Jul 2025 : Collaborative research agreement with Remission Biotech

  • 25 Apr 2025 : Poster Presentations, AACR Annual Meeting, Chicago, USA (Jing Yi Lee, Bavani Kannan)

  • 07 Dec 2024 : Poster Presentations, ASH Annual Meeting, New Orleans, USA

  • 11 Oct 2024 : MOU signed with DxD Hub, A*STAR; Collaborative research agreement with PacBio and KITKOJI

  • 14 Jun 2024 : Poster Presentations, EHA Congress, Madrid, Spain (Boon Yee Lim) 

  • 10 Apr 2024 : Poster Presentations + Scholar-in-Training Award, AACR Annual Meeting, San Diego, USA (Jing Yi Lee, Tun Kiat Ko)

  • 02 Apr 2024 : Collaborative research agreement with Illumina

  • 01 Nov 2023 : Poster Presentation, CTOS Annual Meeting, Dublin (Elizabeth Lee)​​

  • 15 Sep 2023 : MOU and RCA signed with Agilent Technologies, BioSyngen, BGI Research and MGI Tech

  • 14 Jun 2023 : Poster Presentation, ICML Lugano, Switzerland​

  • 14 Apr 2023 : Poster Presentation, AACR Annual Meeting, Florida, USA (Bavani Kannan)​​​​​

  • 20 Mar 2023 : ESMO Merit Award, ESMO Sarcoma and Rare Cancers Congress, Lugano, Switzerland​

  • 18 Mar 2023 : Co-organizer, Singapore Lymphoma Scientific Symposium 2023

  • 12 Dec 2022 : Oral abstract, ASH Annual Meeting, New Orleans, USA​​

  • 09 Dec 2022 : Invited presentation, Stem Cell Society Singapore (SCSS) Symposium (Nimmi Baby)

  • 17 Nov 2022 : Oral paper, CTOS Annual Meeting, Vancouver, Canada (Jing Yi Lee)​

  • 19 Aug 2022 : Invited speech, 6th International BRCA Forum, Singapore​​

  • 19 Aug 2022 : Collaborative research agreement with Scinnohub Pharmaceutical

  • 19 Aug 2022 : Collaborative research agreement with MGI Tech

  • 04 Aug 2022 : Collaborative research agreement with Twist Bioscience

  • 16 Jun 2022 : Best Oral Presentation, International Congress of the Asian Oncology Society (AOS 2022), South Korea (Tun Kiat Ko)​

  • 12 Apr 2022 : Invited Oral Presentation at Major Symposium, AACR Annual Meeting, New Orleans, US

  • 22 Feb 2022 : Publication on circulating tumor DNA mutations in progressive gastrointestinal stromal tumors, Frontiers in Oncology

  • 17 Feb 2022 : Travel Award for Poster abstract at Japanese Society of Medical Oncology Annual Meeting, Japan (Elizabeth Lee)​​

  • ​​12 Jan 2022 : Commercial launch of the UNITED NGS Assay (Lucence) for Asian prevalent cancers at the NCCS

  • 21 Oct 2021 : Collaborative research agreement with STEMCELL Technologies

  • 01 Sep 2021 : Collaborative research agreement with SymBio Pharmaceuticals on EBV-positive lymphomas

  • 01 Sep 2021 : Official launch of Cancer Discovery Hub!

Featured Publications

Scientific publications supported by the Cancer Discovery Hub

A Phase I/II Trial of Anti-CD22/CD19 CAR-T Cell Therapy, CART2219.1, in Adult and Pediatric Relapsed/Refractory B-ALL Blood Cancer Discovery. 2026

Sep, 2026

Durable remissions after anti-CD19 chimeric antigen receptor T cell (CAR-T) therapy in relapsed/refractory B-lineage acute lymphoblastic leukaemia are limited by antigen escape and T-cell dysfunction. The tandem CAR22-19/LTG2737 construct links human-derived anti-CD22 and anti-CD19 scFvs to CD8 hinge/transmembrane, 4-1BB, and CD3ζ domains. In a multicentre phase I/II trial, all patients (n=11; 7 children, 4 adults) achieved complete remission by Day 28 (91% minimal residual disease-negative). At a 34-month median follow-up, median overall survival (OS) and leukaemia-free survival (LFS) were not reached. The 12-month OS was 82% (95%CI: 45%-95%) and LFS was 64% (95%CI: 30%-85%) without consolidative transplantation. Immune-effector cell-associated toxicities included cytokine release syndrome, haematotoxicity, and haemophagocytic lymphohistiocytosis-like syndrome. De novo CD19 escape caused one relapse. Exploratory multi-omic profiling linked durable response to higher CD22 antigen density on blasts; pre-infusion CD4 CAR-T cells expressing IL7Rα, LEF1, BACH2, and TCF7 but lower FOXP3; post-infusion NK-like effector CAR-T expansion; and central-memory CAR-T pool maintenance.

bottom of page